2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: B.S.

Poster-Neuroimmunology and disease models

October 25, 2021

Effect of Ocrelizumab on Antibody Responses to EBV

Background: The association between multiple sclerosis (MS) and Epstein-Barr virus (EBV) is well known. Previously, it’s been shown...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Acapella: B-Cell Repletion in Ocrelizumab-Treated Patients

Background: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for treatment of relapsing remitting (RRMS) and primary...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Acapella: Real-World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive MS, Year Four Data

Background: Ocrelizumab (OCR) is a humanized, monoclonal antibody targeting CD20+ B cells and is approved for treatment of relapsing...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Acapella: Hypogammaglobulinemia and JCV Status in Ocrelizumab-Treated Patients, Year Four Data

Background: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for the treatment of relapsing remitting (RRMS) and...

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC